| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
| [2] |
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
|
| [3] |
Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
|
| [4] |
郑树森, 徐骁, 陈峻, 等. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2):275-280.
|
| [5] |
Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis[J]. Hepatology, 2018, 67(1):381-400.
|
| [6] |
Kim Y, Stahl CC, Makramalla A, et al. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria[J]. Surgery, 2017, 162(6):1250-1258.
|
| [7] |
Werner JD, Frangakis C, Ruck JM, et al. Neoadjuvant transarterial chemoembolization improves survival after liver transplant in patients with hepatocellular carcinoma[J]. Exp Clin Transplant, 2019, 17(5):638-643.
|
| [8] |
高飞, 庞志刚, 韩斌, 等. 肝动脉化疗栓塞联合射频消融术治疗大肝癌的疗效及生存分析[J]. 介入放射学杂志, 2016, 25(4):316-319.
|
| [9] |
李川江, 周杰. 肝细胞肝癌经肝动脉化疗栓塞联合索拉非尼降期后二期切除的初步报告[J]. 腹部外科, 2017, 30(4):295-298, 301.
|
| [10] |
Lyu N, Kong Y, Pan T, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread[J]. J Vasc Interv Radiol, 2019, 30(3):349-357, e2.
|
| [11] |
Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)[J]. Hepatol Res, 2015, 45(2), DOI: 10.1111/hepr.12464.
|
| [12] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19(1):1-20.
|
| [13] |
赵明. 精准医疗时代背景下的肝动脉灌注化疗[J]. 中山大学学报(医学版), 2019, 40(5):648-656.
|
| [14] |
Lee BH, Lee DS, Cho CW, et al. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A[J]. World J Surg Oncol, 2019, 17(1):143.
|
| [15] |
He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1):83.
|
| [16] |
Lewandowski RJ, Donahue L, Chokechanachaisakul A, et al. (90) Yradiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes[J]. J Surg Oncol, 2016, 114(1):99-105.
|
| [17] |
Gabr A, Abouchaleh N, Ali R, et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization[J]. Eur J Radiol, 2017(93): 100-106.
|
| [18] |
Labgaa I, Tabrizian P, Titano J, et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma[J]. HPB, 2019, 21(11):1497-1504.
|
| [19] |
Choi SH, Seong J. Strategic application of radiotherapy for hepatocellular carcinoma[J]. Clin Mol Hepatol, 2018, 24(2):114-134.
|
| [20] |
程树群, 蔡建强, 陈敏山, 等. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]. 临床肝胆病杂志, 2019, 35(4): 737-743.
|
| [21] |
Li N, Feng S, Xue J, et al. Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy[J]. HPB, 2016, 18(6):549-556.
|
| [22] |
Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(11):3308-3315.
|
| [23] |
Assalino M, Terraz S, Grat M, et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion-a multi-center retrospective cohort study[J]. Transpl Int, 2020, 33(5):567-575.
|
| [24] |
杜玉娟, 王佳, 段学章, 等. 原发性肝癌肝移植前射波刀降期治疗(附2例报道)[J]. 肝脏, 2018, 23(6):484-487.
|
| [25] |
Shi F, Wu M, Lian SS, et al. Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: long-term outcomes[J]. Radiology, 2019, 293(3):707-715.
|
| [26] |
Maeda M, Saeki I, Sakaida I, et al. Complications after radiofrequency ablation for hepatocellular carcinoma: a multicenter study involving 9,411 Japanese patients[J]. Liver Cancer, 2020, 9(1): 50-62.
|
| [27] |
张远标, 洪德飞, 范小明, 等. 经皮微波或射频消融肝实质分隔联合门静脉栓塞计划性肝切除术治疗剩余肝体积不足结肠癌肝转移的探索性研究[J]. 中华肿瘤杂志, 2017, 39(7):545-546.
|
| [28] |
蔡涵晖, 邵洁超, 胡智明, 等. 腹腔镜肝切除联合射频消融术在难治性肝癌中的临床应用[J]. 中华普通外科杂志, 2019, 34(5): 417-420.
|
| [29] |
Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phaseⅢ studies[J]. J Hepatol, 2017, 67(5):999-1008.
|
| [30] |
Jeng KS, Huang CC, Lin CC, et al. Liver transplantation after downstagings of ruptured advanced hepatocellular carcinoma in cirrhotic liver: is it advisable? a case report[J]. Transplant Proc, 2019, 51(5):1468-1471.
|
| [31] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
|
| [32] |
Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1):54-63.
|
| [33] |
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled,phase 3 trial[J]. Lancet, 2017, 389(10064):56-66.
|
| [34] |
Liu X, Qin S. Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges[J]. Oncologist, 2019, 24(Suppl 1):S3-10.
|
| [35] |
Kaseb AO, Vence L, Blando J, et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma[J]. Cancer Immunol Res, 2019, 7(9):1390-1395.
|
| [36] |
Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4):571-580.
|
| [37] |
Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3):879-883.
|
| [38] |
邓兰, 蒋益兰, 吴文清, 等. FOLFOX4方案化疗对原发性肝癌患者的临床效果及预后影响因素分析[J]. 实用癌症杂志, 2016, 31(12):1980-1982, 1986.
|
| [39] |
Sinn DH, Choi GS, Park HC, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients[J]. PLoS One, 2019, 14(1):e0210730.
|
| [40] |
罗德, 朱刚, 罗斌, 等. 2例肝癌综合降期治疗的MDT讨论[J]. 中国普外基础与临床杂志, 2020, 27(5):600-605.
|
| [41] |
姜中豪,戴朝六.多学科综合治疗时代肝癌外科新理念[J/CD].中华普通外科学文献(电子版), 2020, 14(6):401-405.
|